Long-term outcomes and hence the role of adjuvant
therapy in patients with small (≤1 cm), node-negative
breast cancer remain unclear. This study's objective was to evaluate whether human
epidermal growth factor receptor (HER)-2 status is an independent, poor prognostic marker in patients with these
tumors and to identify a subgroup of patients with these small
tumors who might benefit from adjuvant systemic
therapy. All patients with a diagnosis of a node-negative
breast tumor measuring ≤1 cm and available HER-2 test results between January 1, 2001, and December 31, 2005, at the three Mayo Clinic sites were identified. Clinicopathologic data were compared in three groups: HER-2(-), HER-2(+), and triple-negative (TN)
tumors. Of the 421
tumors identified, 364 (86.5%) were HER-2(-), 28 (6.7%) were HER-2(+), and 29 (6.9%) were TN. The median follow-up time was 1,015 days (range, 1-2,549 days). Groups were balanced in terms of patient age and
tumor histology. Eleven patients with HER-2(-)
tumors (3.0%), seven with HER-2(+)
tumors (25.0%), and eight with TN
tumors (27.6%) received
adjuvant chemotherapy. Follow-up data were available for 357, 28, and 28 patients in the three groups, respectively. Death rates in the three groups were 6.4% (23 of 357) (one recurrence-related death), 0% (0 of 28), and 7.1% (2 of 28) (one recurrence-related death), respectively. During follow-up, the
tumor recurred in nine patients: four were HER-2(-)
tumors (1.1%), two were HER-2(+)
tumors (7.1%), and three were TN
tumors (10.7%). Patients with small, node-negative
breast tumors have an excellent prognosis, but HER-2(+) and TN
tumors appear to have a higher recurrence rate, warranting consideration for broad use and optimization of systemic adjuvant treatments.